Correction to "Benefit of Axicabtagene Ciloleucel Versus Chemoimmunotherapy in Older Patients and/or Patients With Poor ECOG Performance Status With Relapsed or Refractory Large B-Cell Lymphoma After 2 or More Lines of Prior Therapy"

Am J Hematol. 2025 Jun;100(6):1109. doi: 10.1002/ajh.27674. Epub 2025 Apr 4.
No abstract available

Publication types

  • Published Erratum